Samuel Lee, MD, MBA

Dr. Samuel Lee has a diverse work experience. In 2019, they co-founded, became President, and Chief Business Officer of Eikonoklastes Therapeutics, Inc., where they are developing a pipeline of disruptive new therapies. From 2016 to 2019, they served as an Executive In Residence, Director, and Principal, Life Sciences at CincyTech USA. Since 2019, they have been an angel investor for Beacons, VastBiome, Swift Solar, Haus, Vincere Biosciences, Copy.ai, and Songclip. In 2022, they will become an angel investor for American Gene Technologies International Inc.

Samuel Lee, MD, MBA holds a Bachelor of Arts in Biochemistry from Miami University, a Doctor of Medicine from the University of Cincinnati, a Masters in Public Health & Health Care Management from The Johns Hopkins University, and a Business Administration and Entrepreneurship degree from Stanford University Graduate School of Business.